CA2923476C - Method of reducing neuronal cell death with haloalkylamines - Google Patents

Method of reducing neuronal cell death with haloalkylamines Download PDF

Info

Publication number
CA2923476C
CA2923476C CA2923476A CA2923476A CA2923476C CA 2923476 C CA2923476 C CA 2923476C CA 2923476 A CA2923476 A CA 2923476A CA 2923476 A CA2923476 A CA 2923476A CA 2923476 C CA2923476 C CA 2923476C
Authority
CA
Canada
Prior art keywords
haloalkylamine
tbi
pharmaceutical composition
event
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2923476A
Other languages
English (en)
French (fr)
Other versions
CA2923476A1 (en
Inventor
David J. Poulsen
Thomas Frederick Rau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montana Missoula
Original Assignee
University of Montana Missoula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Montana Missoula filed Critical University of Montana Missoula
Publication of CA2923476A1 publication Critical patent/CA2923476A1/en
Application granted granted Critical
Publication of CA2923476C publication Critical patent/CA2923476C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2923476A 2013-09-06 2014-09-08 Method of reducing neuronal cell death with haloalkylamines Expired - Fee Related CA2923476C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874865P 2013-09-06 2013-09-06
US61/874,865 2013-09-06
PCT/US2014/054569 WO2015035308A2 (en) 2013-09-06 2014-09-08 Method of reducing neuronal cell death with haloalkylamines

Publications (2)

Publication Number Publication Date
CA2923476A1 CA2923476A1 (en) 2015-03-12
CA2923476C true CA2923476C (en) 2021-03-16

Family

ID=52629091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2923476A Expired - Fee Related CA2923476C (en) 2013-09-06 2014-09-08 Method of reducing neuronal cell death with haloalkylamines

Country Status (7)

Country Link
US (3) US20160220515A1 (https=)
EP (1) EP3041465B1 (https=)
JP (3) JP6475733B2 (https=)
CN (2) CN105530924A (https=)
CA (1) CA2923476C (https=)
MX (1) MX376515B (https=)
WO (1) WO2015035308A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041465B1 (en) * 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5513661A (en) 1993-10-14 1996-05-07 Hubbard; David R. Use of sympathetic blockade for treatment of chronic muscle pain
US6009875A (en) 1993-10-14 2000-01-04 Berlex Laboratories, Inc. Use of sympathetic antagonists for treatment of chronic muscle pain
WO1997007793A1 (en) * 1995-08-29 1997-03-06 New York Medical College Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd)
EP1235563A2 (en) 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
CA2416650C (en) 2000-07-19 2010-09-21 Pitmy International N.V. Enhancement of the action of central and peripheral nervous system agents
US6730667B2 (en) 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
US7172614B2 (en) * 2002-06-27 2007-02-06 Advanced Cardiovascular Systems, Inc. Support structures for embolic filtering devices
US20040063612A1 (en) * 2002-09-26 2004-04-01 Manssur Yalpani Neuroprotective agents
US7600349B2 (en) * 2003-02-26 2009-10-13 Unirac, Inc. Low profile mounting system
US20060128719A1 (en) * 2004-12-13 2006-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
WO2007062862A2 (en) 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
US20070249725A1 (en) 2006-02-17 2007-10-25 Hubbard David R Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
MX2009001966A (es) 2006-08-23 2009-06-19 Univ Montana Metodo de reduccion del daño celular neuronal.
US20090197969A1 (en) * 2006-08-23 2009-08-06 Poulsen David J Method of reducing brain cell damage or death
US20110105621A1 (en) * 2006-08-23 2011-05-05 The University Of Montana Method of reducing brain cell damage, inflammation or death
ES2475193T3 (es) 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US8292830B2 (en) 2007-05-22 2012-10-23 University Of Louisville Research Foundation, Inc. Soft tissue impact assessment device and system
WO2010148519A1 (en) 2009-06-25 2010-12-29 Queen's University At Kingston Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
CN102946896A (zh) * 2010-04-30 2013-02-27 西安大略大学 Sox9抑制剂
WO2012074561A2 (en) 2010-11-30 2012-06-07 Columbia Northwest Pharmaceuticals Llc Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
EP2466311A1 (en) 2010-12-17 2012-06-20 Roche Diagnostics GmbH sFlt1 in patients with ischemic stroke
CA2768796A1 (en) 2011-02-22 2012-08-22 Wellspring Pharmaceutical Corporation Phenoxybenzamine assay
WO2012162364A1 (en) * 2011-05-23 2012-11-29 New York Medical College Phenoxybenzamine for pain
US20140371322A1 (en) 2013-06-13 2014-12-18 Professional Compounding Centers Of America Phenoxybenzamine Transdermal Composition
EP3041465B1 (en) 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Also Published As

Publication number Publication date
WO2015035308A3 (en) 2015-10-29
MX2016002655A (es) 2016-06-06
JP2019077718A (ja) 2019-05-23
EP3041465B1 (en) 2020-11-11
JP6636660B2 (ja) 2020-01-29
JP6865806B2 (ja) 2021-04-28
EP3041465A4 (en) 2017-03-08
US20210093586A1 (en) 2021-04-01
CN110251496A (zh) 2019-09-20
JP2016529320A (ja) 2016-09-23
EP3041465A2 (en) 2016-07-13
US20190083423A1 (en) 2019-03-21
CA2923476A1 (en) 2015-03-12
CN105530924A (zh) 2016-04-27
US10849865B2 (en) 2020-12-01
WO2015035308A2 (en) 2015-03-12
US20160220515A1 (en) 2016-08-04
JP2020059746A (ja) 2020-04-16
MX376515B (es) 2025-03-07
JP6475733B2 (ja) 2019-02-27

Similar Documents

Publication Publication Date Title
Sikiric et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications
JP2022514526A (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
CN102470124B (zh) 细胞保护剂
JP2022504944A (ja) Ｎａｄ＋またはｎａｄ＋前駆体と組み合わせたｓａｒｍ１の阻害
RS56523B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
JP2021526507A (ja) 発作により誘発される突然死を処置するための組成物および方法
KR101494675B1 (ko) 신경 세포 손상을 감소시키는 방법
ES2943585T3 (es) Remielinización estimulada por IgG de nervios periféricos
JP6180417B2 (ja) 心不全またはニューロン損傷の治療剤製造のための化合物の使用
US20210093586A1 (en) Method of reducing neuronal cell death with haloalkylamines
CN113069458A (zh) 哌唑嗪用于制备治疗和/或预防脑血管疾病药物中的应用
KR20210061357A (ko) 통증을 치료하기 위해 페녹시프로필아민 화합물을 사용하는 방법
US20210236594A1 (en) Methods for improving frailty and aging
HK40012264A (en) Method of reducing neuronal cell death with haloalkylamines
MD4522143T2 (ro) Tratamentul durerii asociate cu sensibilizare centrală
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
CN103990147B (zh) Toll作用蛋白（Tollip）在脑卒中疾病中的应用
ES2869887T3 (es) Agonistas de blt2 para el tratamiento del dolor
JP2005314347A (ja) 疼痛抑制剤
CN103239440A (zh) 米格列奈在制备治疗缺血性脑卒中药物中的应用
Korimová et al. Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat
JP2018173307A (ja) 末梢神経又は脊髄に存在する膜に特異的に結合して鎮痛作用を有する候補化合物のスクリーニング方法
WO2019211783A1 (en) Indoleamine 2,3-dioxygenase signalling modulator and therapeutic use thereof
El Beheiry et al. Chelation of intra neuronal free calcium opposes anaesthetic actions in aged animals: 9AP1-9
Martins et al. Glyceryl trinitrate for cerebral malaria

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190312

MKLA Lapsed

Effective date: 20220908